Background: Alemtuzumab and natalizumab are approved as second-line therapies for
relapsing-remitting multiple sclerosis (RRMS) patients in Iran who have shown an …

Background Amyotrophic lateral sclerosis (ALS) is an irreversible degenerative disease.
Placebo-controlled randomized trials are currently the main trial design to assess the clinical …

Objective The current study sought to develop a new indicator for disease progression rate
in amyotrophic lateral sclerosis (ALS). Methods We used a nonparametric method to score …

We developed a preference‐based measure, the Amyotrophic Lateral Sclerosis Utility Index
(ALSUI), allowing computation of US population‐based utility weights for the wide range of …

Background Better predictors of amyotrophic lateral sclerosis disease course could enable
smaller and more targeted clinical trials. Partially to address this aim, the Prize for Life …

Objective To assess the effect of eligibility criteria on exclusion rates, generalizability, and
outcome heterogeneity in amyotrophic lateral sclerosis (ALS) clinical trials and to assess the …

Clinical trials in amyotrophic lateral sclerosis (ALS) aim to identify treatments that can slow
functional decline or prolong survival time. In the absence of objective biomarkers …

The revised ALS functional rating scale (ALSFRS-R) is a longitudinal measure of global
function commonly used to assess progression of amyotrophic lateral sclerosis (ALS), and …

Background Edaravone slowed the rate of functional decline in subjects with amyotrophic
lateral sclerosis (ALS) in phase 3 study MCI186-19 (Study 19). One of the Study 19 inclusion …

Abstract Background The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
(ALSFRS-R) total score is a widely used measure of functional status in Amyotrophic Lateral …